DOI:
10.1055/s-00000069
Seminars in Liver Disease
LinksClose Window
References
A randomized, double-blind multicenter phase III study of brivanib versus sorafenib as first-line treatment in patients with hepatocellular carcinoma (BRISK-FL).
Available at:
http://clinicaltrials.gov/ct2/show/NCT00858871 . Accessed January 11, 2012
We do not assume any responsibility for the contents of the web pages of other providers.